. Author manuscript; available in PMC: 2013 Jun 1.

Published in final edited form as: Infect Control Hosp Epidemiol. 2012 Apr 13;33(6):589–593. doi: 10.1086/665721

TABLE 2.

Susceptibility of Pseudomonas aeruginosa Isolates Susceptible to Targeted Antibiotics Based on Site of Care (Inpatient vs Outpatient and Inpatient Intensive Care Units [ICUs] vs Non-ICU)

Antibiotic	Study antibiogram, % (n = 3,393)^a	Inpatient isolates (n = 2,302)^a	Outpatient isolates (n = 1,091)^a	P	Isolates from ICUs (n = 644)^b	Isolates from non-ICU inpatients (n = 1,658)^b	P
Amikacin	95.0	2,192 (95)	1,023 (94)	.09	617 (96)	1,575 (95)	.55
Ceftazidime	89.3	1,994 (87)	1,034 (95)	<.0001	504 (78)	1,490 (90)	<.0001
Ciprofloxacin	72.8	1,439 (71)	734 (77)	.0004	404 (65)	1,035 (73)	<.0001
Gentamicin	80.4	1,831 (80)	892 (82)	.10	497 (77)	1,334 (81)	.07
Imipenem-cilastin	90.8	2,043 (89)	1,024 (94)	<.0001	525 (82)	1,518 (92)	<.0001
Piperacillin-tazobactam	93.3	2,107 (92)	1,059 (97)	<.0001	561 (87)	1,546 (93)	<.0001
Tobramycin	92.6	2,103 (92)	1,035 (95)	.0002	565 (88)	1,538 (93)	<.0001

NOTE. All data are no. (%) unless otherwise indicated.

Susceptibility data were missing for the following antibiotics: amikacin (n =7), ceftazidime (n =1), ciprofloxacin (n =407), gentamicin (n =5), imipenem-cilastin (n =14), and tobramycin (n =5).

Susceptibility data were missing for the following antibiotics: amikacin (n =4), ceftazidime (n =1), ciprofloxacin (n =269), gentamicin (n =2), imipenem-cilastin (n =8), and tobramycin (n =3).